OSE Immuno - First positive clinical results from OSE-279
*OSE shared Ph1/2 results from the first 13 patients, with 8 advanced tumor types, treated with anti-PD1 antibody OSE-279 in monotherapy.*Three partial responses (of which 2 unconfirmed) and 3 stable diseases. We consider this a rather modest outcome so far but acknowledge the advanced disease stage of the enrolled patients. We await the full results of this study to gain a more comprehensive view on the asset's efficacy profile and for which cancer indications OSE-279 displays most potential. Overall, we believe that OSE-279's biggest value lies in combination therapy and as backbone of the BiCKI® platform.*We stick to our BuyOse Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.